Martin Zapata Laguado, Clinical Oncologist at the National Cancer Institute E.S.E., shared on X:
“ASCO 2025 new players in the management of mRCC patients with casdatifan plus a great TKI, shows similar data on toxicity compared to others antihif therapies.”
